Aerosol chemo spray shows promise for Hard-to-Treat ovarian cancer

NCT ID NCT04811703

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a pressurized spray directly into the abdomen, combined with standard IV chemo. The goal is to find the safest dose and see if this combination can make tumors removable by surgery. About 15 women will take part in this early-stage safety trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL CARCINOMA OF THE FALLOPIAN TUBES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpital Claude Huriez - Chirurgie générale et digestive

    RECRUITING

    Lille, France

    Contact Email: •••••@•••••

    Contact

  • Hôpital Claude Huriez - Oncologie médicale

    RECRUITING

    Lille, France

    Contact Email: •••••@•••••

    Contact

  • Hôpital Lyon Sud - Chirurgie Digestive et Oncologique

    RECRUITING

    Pierre-Bénite, 69495, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hôpital Lyon Sud - Chirurgie Gynécologique et oncologique-obstétrique

    RECRUITING

    Pierre-Bénite, France

    Contact Email: •••••@•••••

    Contact

  • Hôpital Lyon Sud - Oncologie Médicale

    RECRUITING

    Pierre-Bénite, France

    Contact

    Contact Email: •••••@•••••

  • Hôpital de la Croix-Rousse

    RECRUITING

    Lyon, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.